Study register · detail
Unclear
GRADE
Very low
66 citations
SamplePräklinisch
ControlNormal endometrium/myometrium
EndpointApoptotic cell index
Blindingn.a.
DesignPräklinisch
Key finding
Preclinical study shows that endocannabinoids can modulate apoptosis in endometriosis and adenomyosis tissue; CB1/CB2 receptor agonists show dose-dependent pro-apoptotic effects in cell lines.
Summary
In vitro study on human endometrial stromal cells and epithelial cells from endometriosis and adenomyosis patients; endocannabinoids (anandamide, 2-AG) modulate apoptosis via CB1/CB2 receptors, significant reduction in cell viability at higher concentrations (p0.05), mechanistic evidence for antiproliferative effects.
P
PopulationPatients with endometriosis and adenomyosis (tissue samples); in vitro: Ishikawa cell line (endometrial carcinoma) and CRL-7566 (ovarian endometriosis stromal cells)
I
InterventionCB1 and CB2 receptor agonists (in vitro, dose-dependent)
C
ControlNormal endometrium/myometrium (immunohistochemical control group); untreated cell cultures
O
OutcomeCB1/CB2 receptors and enzymes (FAAH, NAPE-PLD, MAGL, DAGL) significantly reduced in diseased tissue (p<0,002); apoptotic index significantly lower (p=0,001); agonists induce apoptosis dose-dependently in vitro
Confidence in the evidence
Very low
The lowest GRADE level, the effect estimate remains uncertain.
Quality profile
Sample size
—
Blinding
—
Effect size
—
Citations / year
★★★★★
Authors
Share
Abstract
Adenomyosis that is a form of endometriosis is the growth of ectopic endometrial tissue within the muscular wall of the uterus (myometrium), which may cause dysmenorrhea and infertility. Endocannabinoid mediated apoptotic mechanisms of endometriosis and adenomyosis are not known. We hypothesized that the down regulation of endocannabinoid receptors and/or alteration in their regulatory enzymes may have a direct role in the pathogenesis of endometriosis and adenomyosis through apoptosis. Endocannabinoid receptors CB1 and CB2, their synthesizing and catabolizing enzymes (FAAH, NAPE-PLD, DAGL, MAGL) and the apoptotic indexes were immunohistochemically assessed in endometriotic and adenomyotic tissues. Findings were compared to normal endometrium and myometrium. Endometrial adenocarcinoma (Ishikawa) and ovarian endometriosis cyst wall stromal (CRL-7566) cell lines were furthermore cultured with or without cannabinoid receptor agonists. The IC50 value for CB1 and CB2 receptor agonists was quantified. Cannabinoid agonists on cell death were investigated by Annexin-V/Propidium iodide labeling with flow cytometry. CB1 and CB2 receptor levels decreased in endometriotic and adenomyotic tissues compared to the control group (p=0,001 and p=0,001). FAAH, NAPE-PLD, MAGL and DAGL enzyme levels decreased in endometriotic and adenomyotic tissues compared to control (p=0,001, p=0,001, p=0,001 and p=0,002 respectively). Apoptotic cell indexes both in endometriotic and adenomyotic tissues also decreased significantly, compared to the control group (p=0,001 and p=0,001). CB1 and CB2 receptor agonist mediated dose dependent fast anti-proliferative and pro-apoptotic effects were detected in Ishikawa and ovarian endometriosis cyst wall stromal cell lines (CRL-7566). Endocannabinoids are suggested to increase apoptosis mechanisms in endometriosis and adenomyosis. CB1 and CB2 antagonists can be considered as potential medical therapeutic agents for endometriosis and adenomyosis.
The impediment to action advances action.